Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma

被引：102
作者：
Tangkijvanich, Pisit
Hourpai, Nusara
Rattanatanyong, Prakasit
Wisedopas, Naruemon
Mahachai, Varocha
Mutirangura, Apiwat [1 ]
机构：
[1] Chulalongkorn Univ, Fac Med, Dept Anat, Mol Biol & Genet Canc Dev Res Unit, Bangkok 10330, Thailand
[2] Chulalongkorn Univ, Fac Med, Dept Biochem, Bangkok 10330, Thailand
[3] Chulalongkorn Univ, Fac Med, Dept Pathol, Bangkok 10330, Thailand
[4] Chulalongkorn Univ, Fac Med, Dept Med, Bangkok 10330, Thailand
来源：
CLINICA CHIMICA ACTA | 2007年 / 379卷 / 1-2期
关键词：
global hypomethylation; prognostic marker; hepatocellular carcinoma; COBRA LINE-1; hepatoma;
D O I：
10.1016/j.cca.2006.12.029
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
Background: We investigated the clinical implications of global hypomethylation, one of the most consistent epigenetic changes in cancer, in the sera of patients with hepatocellular carcinoma (HCC). Methods: Combined bisulfite restriction analysis PCR was used to assess the methylation status of LINE-1 repetitive sequences in genomic DNA derived from sera of 85 patients with HCC, 73 patients with cirrhosis, 20 healthy carriers of hepatitis B virus (HBV) and 30 healthy controls. Results: Serum genome hypomethylation, the percentage of unmethylated LINE-1, was significantly increased in patients with HCC (P<0.001). The levels of serum LINE-1 hypomethylation at initial presentation correlated significantly with the presence of HBsAg, large tumor sizes, and advanced tumor stages classified by the CLIP score. Multivariate analyses showed that serum LINE-1 hypomethylation was a significant and independent prognostic factor of overall survival. Conclusion: Serum LINE-1 hypomethylation may serve as a prognostic marker for patients with HCC. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码：127 / 133
页数：7
相关论文
共 31 条
[1]   Circulating nucleic acids in plasma or serum [J].
Anker, P ;
Lyautey, J ;
Lederrey, C ;
Stroun, M .
CLINICA CHIMICA ACTA, 2001, 313 (1-2) :143-146
[2]   Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? [J].
Brothman, AR ;
Swanson, G ;
Maxwell, TM ;
Cui, J ;
Murphy, KJ ;
Herrick, J ;
Speights, VO ;
Isaac, J ;
Rohr, LR .
CANCER GENETICS AND CYTOGENETICS, 2005, 156 (01) :31-36
[3]   Hepatocellular carcinoma: Current management and future trends [J].
Carr, BI .
GASTROENTEROLOGY, 2004, 127 (05) :S218-S224
[4]   Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis [J].
Chalitchagorn, K ;
Shuangshoti, S ;
Hourpai, N ;
Kongruttanachok, N ;
Tangkijvanich, P ;
Thong-ngam, D ;
Voravud, N ;
Sriuranpong, V ;
Mutirangura, A .
ONCOGENE, 2004, 23 (54) :8841-8846
[5]   Timeline - The history of cancer epigenetics [J].
Feinberg, AP ;
Tycko, B .
NATURE REVIEWS CANCER, 2004, 4 (02) :143-153
[6]   DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas [J].
Florl, AR ;
Löwer, R ;
Schmitz-Dräger, BJ ;
Schulz, WA .
BRITISH JOURNAL OF CANCER, 1999, 80 (09) :1312-1321
[7]   The human LINE-1 retrotransposon creates DNA double-strand breaks [J].
Gasior, SL ;
Wakeman, TP ;
Xu, B ;
Deininger, PL .
JOURNAL OF MOLECULAR BIOLOGY, 2006, 357 (05) :1383-1393
[8]   Induction of tumors in mice by genomic hypomethylation [J].
Gaudet, F ;
Hodgson, JG ;
Eden, A ;
Jackson-Grusby, L ;
Dausman, J ;
Gray, JW ;
Leonhardt, H ;
Jaenisch, R .
SCIENCE, 2003, 300 (5618) :489-492
[9]   Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation [J].
Herman, JG ;
Baylin, SB .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :2042-2054
[10]   Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands [J].
Herman, JG ;
Graff, JR ;
Myohanen, S ;
Nelkin, BD ;
Baylin, SB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (18) :9821-9826
1234